Atopic dermatitis is characterized by redness, itching, swelling, and possible scabbing, crusting, oozing, and crusty skin. All sufferers share a similar skin characteristic: their skin is oily and sensitive, with little or no protection from allergens. Although atopic dermatitis can affect anyone, it is most common in children and infants, because their pores are so small and the allergens easier to find.
The global eczema therapeutics market is expected to record CAGR of 11.1% during 2022-2028 and was valued at US$ 15,453.4 million in 2021.
Get Free Sample PDF Copy (Including Full TOC, List of Tables & Figures, Chart) @
Approval and launch of new products is expected to propel growth of the global eczema therapeutics market over the forecast period. For example, European Medicines Agency’s Committee for Medicinal Products for Human Use, in June 2021, approved RINVOQ (upadacitinib), an oral, selective, and reversible JAK inhibitor, from AbbVie Inc. The drug is intended for the treatment of atopic dermatitis.
R&D of new products is expected to offer lucrative growth opportunities for players in the global eczema therapeutics market. For example, in 2020, Pfizer Inc. reported positive Phase 3 results for Abrocitinib, an oral once-daily Janus kinase 1 (JAK1) inhibitor, for the treatment of atopic dermatitis or eczema in adults.
Covid-19 Impact Analysis
In April 2021, European Medicines Agencies conducted a clinical trial in order to evaluate the usage of Olumiant (baricitinib) – an immunosuppressant used for the treatment of rheumatoid arthritis and atopic dermatitis, for the treatment of COVID-19 in hospitalized patients of age 10 who required supplemental oxygen.
Delays in the drug approvals and termination of the clinical trials is expected to limit growth of the global eczema therapeutics market. For example, in June 2021, the decisions for Rinvoq from AbbVie Inc. and Olumiant from Eli Lily and Company, both indicated for the treatment of moderate to severe atopic dermatitis, were delayed by the U.S. Food and Drug Administration. In 2019, Galapagos NV and MorphoSys AG parted ways with Novartis AG for R&D of MOR106 for the treatment of atopic dermatitis as Novartis AG reported negative results during the Phase II trial for MOR106.
Request PDF Brochure with Latest Insights @
Major players operating in the global eczema therapeutics market include, AbbieVie Inc., AstraZeneca plc, Astellas Pharma Inc., Anacor Pharmaceuticals Inc., Encore Dermatology Inc., F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Meda AB, Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., and Sanofi S.A.
On the basis of treatment, the global eczema therapeutics market is segmented into:
- Calcineurin inhibitors
- Interleukin inhibitors
On the basis of distribution channel, the global eczema therapeutics market is segmented into:
- Hospital and Clinics
- Retail Pharmacies
- Online Pharmacies
On the basis of region, the global eczema therapeutics market is segmented into:
- North America
- Latin America
- Asia Pacific
- Middle East
Reasons to buy this Eczema Therapeutics Market Report
◘ Save time carrying out entry-level research by identifying the size, growth, and leading players in the emerging Eczema Therapeutics Market
◘ Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the emerging Eczema Therapeutics Market
◘ Leading company profiles reveal details of key Eczema Therapeutics Market players emerging five operations and financial performance
◘ Add weight to presentations and pitches by understanding the future growth prospects of the emerging Eczema Therapeutics Market with five year historical forecasts
◘ Compares data from North America, South America, Asia Pacific Europe and Middle East Africa, alongside individual chapters on each region
𝐁𝐮𝐲 𝐓𝐡𝐢𝐬 𝐂𝐨𝐦𝐩𝐥𝐞𝐭𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐑𝐞𝐩𝐨𝐫𝐭 𝐖𝐢𝐭𝐡 𝐅𝐥𝐚𝐭 𝐔𝐒𝐃 𝟐𝟎𝟎𝟎 𝐎𝐟𝐟 @
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Eczema Therapeutics Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Eczema Therapeutics Industry Impact
Chapter 2 Global Eczema Therapeutics Competition by Types, Applications, and Top Regions and Countries
2.1 Global Eczema Therapeutics (Volume and Value) by Type
2.3 Global Eczema Therapeutics (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Eczema Therapeutics Sales, Consumption, Export, Import by Regions
Chapter 5 North America Eczema Therapeutics Market Analysis
Chapter 6 East Asia Eczema Therapeutics Market Analysis
Chapter 7 Europe Eczema Therapeutics Market Analysis
Chapter 8 South Asia Eczema Therapeutics Market Analysis
Chapter 9 Southeast Asia Eczema Therapeutics Market Analysis
Chapter 10 Middle East Eczema Therapeutics Market Analysis
Chapter 11 Africa Eczema Therapeutics Market Analysis
Chapter 12 Oceania Eczema Therapeutics Market Analysis
Chapter 13 South America Eczema Therapeutics Market Analysis
Chapter 14 Company Profiles and Key Figures in Eczema Therapeutics Business
Chapter 15 Global Eczema Therapeutics Market Forecast (2022-2028)
Chapter 16 Conclusions
About Coherent Market Insights
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027